Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
A study conducted over 3 periods to look at the drug in the body.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| 1 | Experimental | Single Oral dose AZD8329 tablet (fasting) |
|
| 2 | Experimental | Single Oral dose AZD8329 solution (fasting) |
|
| 3 | Experimental | Single Oral dose AZD8329 tablet (Fed) |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| AZD8329 | Drug | tablet |
| |
| AZD8329 |
| Measure | Description | Time Frame |
|---|---|---|
| Compare the pharmacokinetics (Cmax and AUC) of the oral solution and the oral solid formulation of AZD8329. | Information will be collected during 48h after each dose. |
| Measure | Description | Time Frame |
|---|---|---|
| Explore the effect of food on the pharmacokinetics (Tmax, T1/2 and CL/F) of AZD8329 oral solid formulation. | Information will be collected during 48h after dose. | |
| Investigate the safety and tolerability of AZD8329 administered as two different oral formulations.(Safety variables: Adverse events, Vital Signs, Clinical chemistry, Electrocardiogram (p ECG)) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| J Ritter, BM BCh, MRCP, FRCP | Quintiles Drug Research Unit at Guy's Hospital | Principal Investigator |
| Dr. Mirjana Kujacic | AstraZeneca Mölndal | Study Chair |
| Jan Eriksson, MD PhD | AstraZeneca Sweden | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Research Site | London Bridge | United Kingdom |
Not provided
| ID | Term |
|---|---|
| D003924 | Diabetes Mellitus, Type 2 |
| ID | Term |
|---|---|
| D003920 | Diabetes Mellitus |
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C000589241 | 4-(4-(2-adamantylcarbamoyl)-5-tert-butyl-pyrazol-1-yl)benzoic acid |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Drug |
Solution |
|
| Adverse event will be collected from first dose to last visit . Clinical chemistry, Vital Signs and pECG's will be collected at all 5 visits |
| D004700 | Endocrine System Diseases |